RxDoctor Payments Data

Ariana Bradley, NP

Nurse Practitioner · Austin, TXNPI 1346842622

Payments from drug & device makers

$3,113in general payments, 2019–2025

Across 148 payments — averaging $21.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$455
  • Novo Nordisk$330
  • Mayne Pharma Commercial LLC$285
  • AbbVie$266
  • GSK$237
  • Amgen$178
  • plus $1K from 24 others

What the payments were for

  • Food & beverage$3,113100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,113 in reported general payments places this provider in the 90th percentile of 5,422 nurse practitioner providers in Texas.

See all nurse practitioner providers in Texas

Medicare billing

Part B allowed, 2024
$36,223
Medicare patients
207
Services billed
527

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide18$16,825
Qnasl ChildrenBeclomethasone Dipropionate12$3,405
SynthroidLevothyroxine Sodium11$787
Rosuvastatin Calcium36$474
Ezetimibe26$423
Fluticasone Propionate33$401
ValacyclovirValacyclovir Hcl16$385
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav47$315
Atorvastatin Calcium41$306
Omeprazole18$275
Levothyroxine Sodium39$247
Lisinopril29$242
Albuterol Sulfate HfaAlbuterol Sulfate14$225
Celecoxib15$198
Duloxetine Hcl11$194

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$155$16,82518 claims
AbbVieSynthroid$266$78711 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$37$24739 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,422 nurse practitioner providers in Texas.

Other nurse practitioner in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →